HanAll Biopharma is trading at 25,050 KRW as of 10:30 AM on the 4th, up 2.45% from the previous day. The trading volume is 1,548,911 shares, which is 9.96% of the previous day's volume. HanAll Biopharma is known as an R&D-focused pharmaceutical and bio company.
On February 4th, Jaekyung Park, a researcher at DB Financial Investment, stated, "On February 2nd, Immunovant, which is developing HL161 of the company, announced the discontinuation of the clinical trial for IMVT1401 (HL161), and the stock price dropped by 42.08% on the same day. The reason for stopping the trial was the occurrence of cholesterol elevation side effects in the phase 2b clinical trial for thyroid eye disease. The mechanism and cause of the side effects have not yet been confirmed, and there is still a possibility of changing the clinical design to combine with hypercholesterolemia drugs," and set HanAll Biopharma's target price at 46,000 KRW.
Over the past five days, individual investors have net purchased 3,174,102 shares of HanAll Biopharma, while foreigners and institutions have net sold 341,365 shares and 2,809,994 shares, respectively.
※Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
